Literature DB >> 32097300

Enhanced Recovery after Surgery Protocols Decrease Outpatient Opioid Use in Patients Undergoing Abdominally Based Microsurgical Breast Reconstruction.

Juan L Rendon1, Trevor Hodson, Roman J Skoracki, Michelle Humeidan, Albert H Chao.   

Abstract

BACKGROUND: Enhanced recovery after surgery (ERAS) protocols have known benefits in the inpatient setting, but little is known about their impact in the subsequent outpatient setting. On discharge, multimodal analgesia has been discontinued, nerve blocks and pain pumps have worn off, and patients enter a substantially different physical environment, potentially resulting in a rebound effect. The objective of this study was to investigate the effect of ERAS protocol implementation on outpatient opioid use and recovery.
METHODS: Patients who underwent abdominally based microsurgical breast reconstruction before and after ERAS implementation were reviewed retrospectively. Ohio state law mandates that no more than 7 days of opioids may be prescribed at a time, with the details of all prescriptions recorded in a statewide reporting system, from which opioid use was determined.
RESULTS: A total of 105 patients met inclusion criteria, of which 46 (44 percent) were in the pre-ERAS group and 59 (56 percent) were in the ERAS group. Total outpatient morphine milligram equivalents used in the ERAS group were less than in the pre-ERAS group (337.5 morphine milligram equivalents versus 668.8 morphine milligram equivalents, respectively; p =0.016). This difference was specifically significant at postoperative week 1 (p =0.044), with gradual convergence over subsequent weeks. Although opioid use was significantly less in the ERAS group, pain scores in the ERAS group were comparable to those in the pre-ERAS group.
CONCLUSIONS: The benefits of ERAS protocols appear to extend into the outpatient setting, further supporting their use to facilitate recovery, and highlighting their potential role in helping to address the prescription opioid abuse problem. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32097300     DOI: 10.1097/PRS.0000000000006546

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  3 in total

1.  Perioperative Inpatient Opioid Consumption Following Autologous Free-Flap Breast Reconstruction Patients: An Examination of Risk and Patient-Reported Outcomes.

Authors:  Jonas A Nelson; Thais O Polanco; Meghana G Shamsunder; Michelle Coriddi; Evan Matros; Madeleine E V Hicks; Joseph J Disa; Babak J Mehrara; Robert J Allen; Joseph H Dayan; Anoushka Afonso
Journal:  Ann Surg Oncol       Date:  2021-05-06       Impact factor: 4.339

2.  Evaluating the Efficacy of Two Regional Pain Management Modalities in Autologous Breast Reconstruction.

Authors:  Juan L Rendon; Jaume Borrell-Vega; Joshua-Paolo C Reyes; Diana M Wang; Cory Roeth; Mahmoud Abdel-Rasoul; Roman J Skoracki; Ronald L Harter; Susan D Moffatt-Bruce; Michelle L Humeidan
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-01-19

3.  Does An ERAS Protocol Reduce Postoperative Opiate Prescribing in Plastic Surgery?

Authors:  Heather R Faulkner; Suzanne B Coopey; Rachel Sisodia; Bridget N Kelly; Lydia R Maurer; Dan Ellis
Journal:  JPRAS Open       Date:  2021-10-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.